Biotechnology

A novel therapy that disarms rather than kills a deadly superbug offers a glimpse of a post-antibiotic future for patients with a debilitating lung disease.

An acquisition signals more than growth; it’s a strategic redesign of the clinical trial landscape, challenging giants and empowering innovation.

A simple urine test could soon detect cancer early. With $33M in fresh funding, Japanese bio-AI firm Craif is betting its tech can change U.S. healthcare.

The ALS Association's premier conference unites patients, researchers, and advocates to tackle the disease from the lab bench to the insurance appeal.

For families facing the grim prognosis of GM2 gangliosidoses, a new alliance offers a glimmer of hope, revealing the strategic interplay of academia and industry.

A top exec's move from a device giant to a drug startup signals a major shift. Charles Anderson analyzes why hardware's limits in fighting infection are now biotech's biggest opportunity.

Coultreon Biopharma's strategic hire of Dr. Prista Charuworn signals a major push to advance its novel SIK3 inhibitor in the crowded autoimmune market.

A Boston biotech with Korean roots just went public in Seoul. Its goal: to repair the body's smallest blood vessels, a market Merck has already bet billions on.

A free online calculator for an experimental drug seems trivial. But it reveals the hidden operational layer where scientific breakthroughs are forged.

Beyond beta-blockers, a new class of targeted therapies is revolutionizing hypertrophic cardiomyopathy care, sparking a fierce corporate race for market dominance.

A new 'cell mimic' control from Slingshot Bio promises to eliminate a major source of variability in cellular analysis, streamlining complex research workflows.

A new survey reveals the staggering cost of clinical trial delays, but the real story isn't the numbers—it's the systemic breakdown of a fragmented, manual process.

In a strategic pivot, Skye Bioscience acquires Redx Pharma, creating Fibrx Therapeutics—a new Nasdaq-listed player armed with $125M and a bold plan.

New preclinical data shows NurExone's ExoPTEN protects vital nerve coatings, providing a biological basis for functional recovery in spinal cord injury models.

Quoin Pharmaceuticals scores key regulatory wins for its rare skin disease drugs, offering hope where none existed. But can its cash hold out long enough?

PMV Pharma's rezatapopt shows remarkable results for a tough cancer by reactivating a key defense. A deep dive into the science, finances, and patient hope.

As Evaxion prepares its Q2 update, investors watch to see if its AI-Immunology™ platform can deliver the financial and clinical results for long-term value.

Fannin Partners secures key grants to advance its Raptamer therapy for a rare pediatric cancer, highlighting a funding model vital for high-risk innovation.

With a new CEO, a leaner budget, and crucial data on the horizon for its brain and obesity drugs, Neumora is navigating a pivotal phase of growth.

With a novel drug platform and new funding, Akari Therapeutics aims to redefine cancer therapy. But can its groundbreaking science outpace a ticking financial clock?